{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:19:02Z","timestamp":1778591942873,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","award":["MRC-01-17-043"],"award-info":[{"award-number":["MRC-01-17-043"]}],"id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Piperacillin\/tazobactam (PT), when combined with vancomycin, is associated with an increased risk of acute kidney injury (AKI). It is not known whether PT alone is associated with a higher incidence of AKI compared to other \u03b2-lactams among critically ill patients. The objective of this study was to compare the incidence of AKI associated with the use of PT to other \u03b2-lactams among adult critically ill patients<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study was conducted in the surgical and the medical intensive care units at two hospitals within Hamad Medical Corporation (HMC) in Qatar and included adult critically ill patients who received at least one dose of anti-pseudomonal \u03b2-lactams. The primary outcome was acute kidney injury, defined using the Kidney Disease Improving Global Outcomes (KDIGO) criteria. Multiple logistic regression with adjustment for pre-specified potential confounders was used for the primary outcome analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 669 patients were included in the analysis: 507 patients in the PT group and 162 patients in the control (meropenem\/cefepime) group. AKI occurred in 136 (26.8%) members of the PT group and 38 (23.5%) members of the control group [odds ratio (OR) 1.2; 95% confidence interval (CI) 0.79\u20131.8]. The results were not significantly altered after adjusting for the pre-specified potential confounders (adjusted OR 1.38; 95% CI 0.88\u20132.15).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this study, PT was not associated with a higher risk of AKI compared to cefepime or meropenem among adult critically ill patients.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s15010-020-01480-x","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T18:03:38Z","timestamp":1595441018000},"page":"741-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of the risk of acute kidney injury with the use of piperacillin\/tazobactam among adult critically ill patients"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2221-4216","authenticated-orcid":false,"given":"Mohamed O.","family":"Saad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-7049","authenticated-orcid":false,"given":"Adham M.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-8641","authenticated-orcid":false,"given":"Hassan A.","family":"Mitwally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7901-7686","authenticated-orcid":false,"given":"Ahmed A.","family":"Shible","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-5793","authenticated-orcid":false,"given":"Ali","family":"Ait Hssain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5136-3958","authenticated-orcid":false,"given":"Mohamed A.","family":"Abdelaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"1480_CR1","first-page":"203","volume":"43","author":"DJ Curcio","year":"2011","unstructured":"Curcio DJ, Curcio D, Al\u00ed A, Duarte A, Defilippi Pauta A, Guerr\u00f3n AFE, et al. Prescripci\u00f3n de antibi\u00f3ticos en unidades de cuidados intensivos de Latinoam\u00e9rica. Rev Argent Microbiol. 2011;43:203\u201311.","journal-title":"Rev Argent Microbiol"},{"key":"1480_CR2","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1097\/CCM.0000000000001294","volume":"43","author":"Z Thomas","year":"2015","unstructured":"Thomas Z, Bandali F, Sankaranarayanan J, Reardon T, Olsen KM. A multicenter evaluation of prolonged empiric antibiotic therapy in adult ICUs in the United States*. Crit Care Med. 2015;43:2527\u201334.","journal-title":"Crit Care Med"},{"key":"1480_CR3","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.12923","volume":"312","author":"SS Magill","year":"2014","unstructured":"Magill SS, Edwards JR, Beldavs ZG, Dumyati G, Janelle SJ, Kainer MA, et al. Prevalence of antimicrobial use in US Acute Care Hospitals, May-September 2011. JAMA. 2014;312:1438.","journal-title":"JAMA"},{"key":"1480_CR4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13054-018-2112-z","volume":"22","author":"E Peters","year":"2018","unstructured":"Peters E, Antonelli M, Wittebole X, Nanchal R, Fran\u00e7ois B, Sakr Y, et al. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from the intensive care over nations audit. Crit Care. 2018;22:188.","journal-title":"Crit Care"},{"key":"1480_CR5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","volume":"41","author":"EAJ Hoste","year":"2015","unstructured":"Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41:1411\u201323.","journal-title":"Intensive Care Med"},{"key":"1480_CR6","first-page":"38","volume":"37","author":"LAB Peres","year":"2015","unstructured":"Peres LAB, Wandeur V, Matsuo T. Predictors of acute kidney injury and mortality in an Intensive Care Unit. Jornal Brasileiro de Nefrologia. 2015;37:38\u201346.","journal-title":"Jornal Brasileiro de Nefrologia."},{"key":"1480_CR7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0897190016628960","volume":"30","author":"V Peyko","year":"2017","unstructured":"Peyko V, Smalley S, Cohen H. Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin. J Pharm Pract. 2017;30:209\u201313.","journal-title":"J Pharm Pract"},{"key":"1480_CR8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cid\/ciw709","volume":"64","author":"B Navalkele","year":"2017","unstructured":"Navalkele B, Pogue JM, Karino S, Nishan B, Salim M, Solanki S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis. 2017;64:116\u201323.","journal-title":"Clin Infect Dis"},{"key":"1480_CR9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/phar.1428","volume":"34","author":"DM Gomes","year":"2014","unstructured":"Gomes DM, Smotherman C, Birch A, Dupree L, Della Vecchia BJ, Kraemer DF, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy. 2014;34:662\u20139.","journal-title":"Pharmacotherapy."},{"key":"1480_CR10","doi-asserted-by":"crossref","first-page":"e02658","DOI":"10.1128\/AAC.02658-18","volume":"63","author":"AM Blevins","year":"2019","unstructured":"Blevins AM, Lashinsky JN, McCammon C, Kollef M, Micek S, Juang P. Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem. Antimicrob Agents Chemother. 2019;63:e02658\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"1480_CR11","doi-asserted-by":"crossref","first-page":"ciw811","DOI":"10.1093\/cid\/ciw811","volume":"64","author":"DA Hammond","year":"2016","unstructured":"Hammond DA, Smith MN, Li C, Hayes SM, Lusardi K, Bookstaver PB. Systematic Review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam. Clin Infect Dis. 2016;64:ciw811.","journal-title":"Clin Infect Dis."},{"key":"1480_CR12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","volume":"46","author":"MK Luther","year":"2018","unstructured":"Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med US. 2018;46:12\u201320.","journal-title":"Crit Care Med US"},{"key":"1480_CR13","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/phar.1851","volume":"36","author":"CA Giuliano","year":"2016","unstructured":"Giuliano CA, Patel CR, Kale-Pradhan PB. Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A Meta-analysis. Pharmacotherapy. 2016;36:1217\u201328.","journal-title":"Pharmacotherapy."},{"key":"1480_CR14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11739-020-02287-2","volume":"15","author":"T Ciarambino","year":"2020","unstructured":"Ciarambino T, Giannico OV, Campanile A, Tirelli P, Para O, Signoriello G, et al. Acute kidney injury and vancomycin\/piperacillin\/tazobactam in adult patients: a systematic review. Intern Emerg Med. 2020;15:327\u201331.","journal-title":"Intern Emerg Med"},{"key":"1480_CR15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1574886311666161024164859","volume":"12","author":"CK Mellen","year":"2017","unstructured":"Mellen CK, Ryba JE, Rindone JP. Does piperacillin-tazobactam increase the risk of nephrotoxicity when used with vancomycin: a meta-analysis of observational trials. Curr Drug Saf UAE. 2017;12:62\u20136.","journal-title":"Curr Drug Saf UAE"},{"key":"1480_CR16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s10156-013-0605-x","volume":"19","author":"F Karino","year":"2013","unstructured":"Karino F, Miura K, Fuchita H, Koba N, Nishikawa E, Hotta T, et al. Efficacy and safety of piperacillin\/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia. J Infect Chemother. 2013;19:909\u201315.","journal-title":"J Infect Chemother"},{"key":"1480_CR17","doi-asserted-by":"crossref","first-page":"e000635","DOI":"10.1136\/bmjopen-2011-000635","volume":"2","author":"J-US Jensen","year":"2012","unstructured":"Jensen J-US, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open. 2012;2:e000635.","journal-title":"BMJ Open."},{"key":"1480_CR18","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1681\/ASN.2018121223","volume":"30","author":"EL Joyce","year":"2019","unstructured":"Joyce EL, Kane-Gill SL, Priyanka P, Fuhrman DY, Kellum JA. Piperacillin\/tazobactam and antibiotic-associated acute kidney injury in critically ill children. J Am Soc Nephrol. 2019;30:2243\u201351.","journal-title":"J Am Soc Nephrol."},{"key":"1480_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40780-019-0142-6","volume":"5","author":"S Kadomura","year":"2019","unstructured":"Kadomura S, Takekuma Y, Sato Y, Sumi M, Kawamoto K, Itoh T, et al. Higher incidence of acute kidney injury in patients treated with piperacillin\/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study. J Pharm Health Care Sci. 2019;5:1\u20138.","journal-title":"J Pharm Health Care Sci."},{"key":"1480_CR20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2125.2008.03266.x","volume":"66","author":"CB Landersdorfer","year":"2008","unstructured":"Landersdorfer CB, Kirkpatrick CMJ, Kinzig M, Bulitta JB, Holzgrabe U, S\u00f6rgel F. Inhibition of flucloxacillin tubular renal secretion by piperacillin. Br J Clin Pharmacol. 2008;66:648\u201359.","journal-title":"Br J Clin Pharmacol"},{"key":"1480_CR21","first-page":"278","volume":"112","author":"S Kraleti","year":"2016","unstructured":"Kraleti S, Khatri N, Jarrett D. Piperacillin-tazobactam induced interstitial nephritis, hepatitis and serum sickness-like illness. J Ark Med Soc. 2016;112:278\u201380.","journal-title":"J Ark Med Soc."},{"key":"1480_CR22","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1248\/bpb.b14-00362","volume":"37","author":"F Karino","year":"2014","unstructured":"Karino F, Nishimura N, Ishihara N, Moriyama H, Miura K, Hamaguchi S, et al. Nephrotoxicity induced by piperacillin-tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia. Biol Pharm Bull Jpn. 2014;37:1971\u20136.","journal-title":"Biol Pharm Bull Jpn"},{"key":"1480_CR23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijantimicag.2018.11.002","volume":"53","author":"RG Hall","year":"2019","unstructured":"Hall RG, Yoo E, Faust A, Smith T, Goodman E, Mortensen EM, et al. Impact of piperacillin\/tazobactam on nephrotoxicity in patients with Gram-negative bacteraemia. Int J Antimicrob Agents. 2019;53:343\u20136.","journal-title":"Int J Antimicrob Agents."},{"key":"1480_CR24","doi-asserted-by":"crossref","first-page":"R292","DOI":"10.1186\/cc13158","volume":"17","author":"M Hansen","year":"2013","unstructured":"Hansen M, Gammelager H, Mikkelsen M, Hjortdal V, Layton J, Johnsen S, et al. Post-operative acute kidney injury and five-year risk of death, myocardial infarction, and stroke among elective cardiac surgical patients: a cohort study. Crit Care. 2013;17:R292.","journal-title":"Crit Care"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01480-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-020-01480-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01480-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T15:25:14Z","timestamp":1723303514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-020-01480-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1007\/s15010-020-01480-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by Hamad Medical Corporation Medical Research Center as \u201cExempt\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}